In CD44-positive HCC, GANT61 dramatically reduced Hedgehog signalling to reverse sorafenib resistance, demonstrating that sorafenib with Hedgehog signalling inhibitors may be a useful therapeutic strategy for HCC patients with elevated CD44 levels. The gene discussed is CD44; the disease is hepatocellular carcinoma.